Marijn Dekkers

Last updated

Marijn Emmanuel Dekkers (born 22 September 1957 in Tilburg, Netherlands) is a Dutch-American former pharmaceutical businessman. He was CEO of Bayer AG from 2010 to 2016. [1] He was CEO of Thermo Fisher Scientific Inc. from 2002 to 2009. He was Chairman of Unilever from 2016 to 2019. [2] He is also Founder and Chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry.

Contents

Early life

Dekkers grew up as the youngest of three children of a merchant in the Dutch city of Tilburg. After attending local schools, St. Aloysius (primary school) and St. Odulphus (Lyceum), in 1976 he began studying chemistry at the Radboud University in Nijmegen. Three years later he began studying chemical technology at Eindhoven University of Technology, where he received his master's degree and PhD in chemical engineering. [3]

Career

In 1985 Dekkers worked for General Electric (GE) in different research departments located in the US and the Netherlands. In 1988, he became Research Director of the GE range of polymers and subsequently held management positions in various other polymer units.

In 1995, Dekkers joined Allied Signal (later named Honeywell International Inc.) and took over the management of various business units.

In 2000, he became a director at the Boston-based Thermo Electron Corporation, [4] one of the world's leading specialists in the manufacture of laboratory instruments. Within a short time, Dekkers implemented a complete corporate reorganization and became President and CEO in 2002. In this role, he initiated further extensive restructuring measures, divesting various organizational units and strengthening the company's core business by means of targeted acquisitions, including the purchase in 2006 of the laboratory consumables supplier Fisher Scientific. After the acquisition, the company renamed as Thermo Fisher Scientific, which employed 30,000 people in six business groups. [5]

On 1 January 2010 Dekkers was appointed to the board of Bayer AG and on 1 October 2010 he took over as CEO from Werner Wenning. [6] On 3 June 2014 Bayer AG announced that its Supervisory Board had extended Marijn Dekkers' term as CEO by two years, on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016. [7] He left Bayer on 30 April 2016 and was succeeded by Werner Baumann on 1 May 2016. [8]

Since April 2016 he was the Chairman of Unilever until 13 november 2019. [9]

In 2017 Dekkers founded Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry (www.novalislifesciences.com).

In 2019 Dekkers was named Chairman of the Board of Directors of Ginkgo Bioworks, a Synthetic Biology biotech company in Boston. [10]

Awards and recognition

"Manager of the Year 2014" by German business magazine "Manager Magazin" [11]

"Business person of the Year 2015" by the "Finanzen Verlag" publishing group and the readers of its publications "€uro am Sonntag", "€uro" and "Börse online" [12]

"Most Innovative CEO International 2015" by the German industry's "Innovation Award" [13]

Controversy

In 2013 some controversy was sparked during a Financial Times panel discussion with relation to Bayer's kidney and liver cancer drug Nexavar. [14]

He spoke at a conference in 2014, saying [15] [16]

"So now, is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let's be honest. I mean, you know, we developed this product for Western patients who can afford this product, quite honestly." [17] [18] [19]

Médecins Sans Frontières responded to Dekkers' comment, saying that it

sums up everything that is wrong with the multinational pharmaceutical industry. Bayer is effectively admitting that the drugs they develop are deliberately going to be rationed to the wealthiest patients. [20]

Dekkers replied to this, referring to the decision made by the Indian government, not to protect a patent on Nexavar and the intellectual property of Bayer. He also said:

I regret that what was a quick response from me within the framework of a panel discussion at the recent FT Pharma conference has come across in a different way as it was meant by myself. It could not be more opposite to what I want and we do at Bayer. [21]

Personal life

Dekkers holds both Dutch and U.S. citizenship. [22]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Chiron Corporation</span> American biotechnology firm (1981-2006)

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Sorafenib</span> Chemical compound

Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

<span class="mw-page-title-main">Patheon</span>

Patheon is a service brand within Thermo Fisher Scientific’s brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

<span class="mw-page-title-main">PPD, Inc.</span> Global contract research organization

Pharmaceutical Product Development (PPD) is a global contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services. In December 2021, PPD became a wholly owned subsidiary of Thermo Fisher Scientific.

<span class="mw-page-title-main">Bayer</span> German multinational pharmaceutical and biotechnology company

The Bayer AG is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include: pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index.

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company was a publicly traded company listed on NASDAQ under the symbol "AMAG" until November 2020 when it was acquired by Covis Pharma.

<span class="mw-page-title-main">Acceleron Pharma</span> American healthcare company

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

<span class="mw-page-title-main">Werner Baumann</span> German businessman and CEO of Bayer

Werner Baumann is a German businessman who was the chief executive officer (CEO) of Bayer from 2016 to May 2023.

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">Natco Pharma</span> Indian pharmaceutical company

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division.

<span class="mw-page-title-main">Bill Anderson (businessman)</span> American business executive (born 1966)

William Anderson is an American business executive who has been the chief executive officer (CEO) of Bayer AG since June 2023.

Samarth Kulkarni is a biotechnology executive. Kulkarni is the chief executive officer and chairman of the board at CRISPR Therapeutics. He has served as CEO of CRISPR Therapeutics since 2017. He was appointed to CEO and Chairman of CRISPR Therapeutics in 2023.

References

  1. ↑ AG, Bayer. "CV of Dr. Marijn Dekkers". www.bayer.com. Retrieved 2016-05-02.
  2. ↑ "Dr Marijn Dekkers". Unilever global company website. Retrieved 2016-05-02.
  3. ↑ Title of Thesis: The Deformation Behaviour of Glass Beaded-Filled Glassy Polymers
  4. ↑ "Thermo Fisher CEO Dekkers leaves to head Bayer; Casper appointed CEO". www.bizjournals.com. Retrieved 2018-06-06.
  5. ↑ "Thermo Electron, Fisher Scientific in Deal". The Washington Post . ISSN   0190-8286 . Retrieved 2018-06-06.
  6. ↑ "Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 | FierceBiotech". 15 September 2009.
  7. ↑ "Bayer CEO's long goodbye: Dekkers to depart at end of 2016 | FiercePharma".
  8. ↑ AG, Bayer. "Bayer's CEO: Werner Baumann". www.bayer.com. Retrieved 2016-05-02.
  9. ↑ Geen Nederlander meer in top-tandem Unilever
  10. ↑ "Ginkgo Bioworks Appoints Former Bayer CEO Marijn Dekkers as Chairman of its Board of Directors; Cision PR Newswire".
  11. ↑ "Marijn Dekkers ist "Manager des Jahres"".
  12. ↑ "Bayer-Chef Dekkers Unternehmer des Jahres - Kaldemorgen Fondsmanager des Jahres - 03.02.15 - BÖRSE ONLINE".
  13. ↑ "Home". innovationspreis.com.
  14. ↑ The original quote causing the debate was "Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product." – Columbia Journalism Review, January 29, 2014, Videorecording of the panel (19:00 – 19:30) Archived 2014-11-11 at the Wayback Machine
  15. ↑ "Bloomberg's viral misquote".
  16. ↑ "Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar". 2014-02-07.
  17. ↑ "Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for "western patients who can afford it."". 2014-01-23. Archived from the original on 2014-01-24. Retrieved 2014-11-22.
  18. ↑ "Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust - PANEL | Calendar | FT Live". Archived from the original on 2014-11-11. Retrieved 2014-11-20.
  19. ↑ "Pharma drug development only for wealthy countries? - Times of India". The Times of India .
  20. ↑ http://www.msfaccess.org/content/msf-response-bayer-ceo-statement-medicines-developed-only-western-patients. [ dead link ]
  21. ↑ "Does Pharma Only Develop Drugs for Those Who Can Pay?". Forbes .
  22. ↑ "Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 | FierceBiotech". www.fiercebiotech.com. 15 September 2009. Retrieved 2018-06-06.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.